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Abstract
Background: Opioid analgesics such as morphine and meperidine have been used to control moderate to severe pain 
for many years. However, these opioids have many side effects, including the development of tolerance and 
dependence after long-term use, which has limited their clinical use. We previously reported that mutations in the mu-
opioid receptors (MOR) S196L and S196A rendered them responsive to the opioid antagonist naloxone without 
altering the agonist phenotype. In MORS196A knock-in mice, naloxone and naltrexone were antinociceptive but did 
not cause tolerance or physical dependence. In this study we delivery this mutated MOR gene into pain related 
pathway to confirm the possibility of in vivo transfecting MORS196A gene and using naloxone as a new analgesic 
agent.
Methods: The MOR-knockout (MOR-KO) mice were used to investigate whether morphine and naloxone could show 
antinociceptive effects when MORS196A gene was transfected into the spinal cords of MOR-KO mice. Double-stranded 
adeno-associated virus type 2 (dsAAV2) was used to deliver the MORS196A-enhanced green fluorescence protein 
(EGFP) gene by microinjected the virus into the spinal cord (S2/S3) dorsal horn region. Tail-flick test was used to 
measure the antinociceptive effect of drugs.
Results: Morphine (10 mg/kg, s.c.) and naloxone (10 mg/kg, s.c.) had no antinociceptive effects in MOR-KO mice before 
gene transfection. However, two or three weeks after the MOR-S196A gene had been injected locally into the spinal 
cord of MOR-KO mice, significant antinociceptive effects could be induced by naloxone or morphine. On the other 
hand, only morphine but not naloxone induced significant tolerance after sub-chronic treatment.
Conclusion: Transfecting the MORS196A gene into the spinal cord and systemically administering naloxone in MOR-
KO mice activated the exogenously delivered mutant MOR and provided antinociceptive effect without causing 
tolerance. Since naloxone will not activate natural MOR in normal animals or humans, it is expected to produce fewer 
side effects and less tolerance and dependence than traditional opioid agonists do.
Background
Morphine, which acts primarily on the mu-opioid recep-
tors (MOR), is used clinically to control moderate and
severe pain. However, morphine has many adverse side
effects, such as respiratory depression, vomiting, nausea,
constipation, tolerance, and dependence. After prolonged
use, analgesic tolerance develops, which requires dosage
increases to maintain its analgesic effect. This is problem-
atic because dosage increases also increase the frequency
and severity of its side effects. Therefore, developing new
analgesics without these side effects is imperative.
We previously created MORS196A, a single-point
mutation of Ser-196 in the fourth transmembrane
domain of the MOR to Ala [1]. MORS196A recognizes
the opioid antagonist naloxone and naltrexone as partial
agonists. In Chinese hamster ovary cells stably expressing
the S196A mutant, naloxone and naltrexone inhibited
forskolin-stimulated adenylyl cyclase activity. Antago-
nists also activated the G-protein-coupled inwardly recti-
fying potassium channel 1 (GIRK1) in Xenopus oocytes
co-expressing the S196A mutant and the GIRK1 channel.
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The ability of opioid antagonists to activate MORS196A
in vitro was also shown in vivo [2],. Morphine was equally
antinociceptive in homozygous MORS196A knock-in
mice and in wild-type mice. Naloxone and naltrexone
were also antinociceptive but did not cause tolerance or
physical dependence in the MORS196A knock-in mice
[2]. We recently [3] investigated the efficiency of using
double-stranded adeno-associated virus type 2 (dsAAV2)
vectors to deliver the MORS196A-enhanced green fluo-
rescence protein (EGFP) gene into the sacral spinal cord
of healthy wild type Imprinting Control Region (ICR)
mice. We found that a single injection provided sustained
gene expression in the spinal cord for at least 6 months
[3]. In ICR mice expressing the mutant MOR, morphine
induced similar antinociceptive responses and induced
tolerance and withdrawal symptoms and reward effects
similar to those in control mice (only saline injected into
the spinal cord). Conversely, in ICR mice injected with
the mutant MOR gene, naloxone also had antinociceptive
effect, but it had no measurable effect in control mice.
Furthermore, the chronic administration of naloxone to
mice expressing the mutant MOR did not induce toler-
ance, dependence, or reward responses. Because of the
wide distribution of non-mutated MOR in these ICR
mice, we have used MOR -K O mice to further confirm
our findings in the present study.
Methods
Chemicals
Morphine hydrochloride was purchased from the
National Bureau of Controlled Drugs, National Health
Administration, Taipei, Taiwan. Naloxone and naltrexone
were purchased from Sigma-Aldrich Chemical Co. (St.
Louis, MO, USA). All other chemicals were locally pur-
chased and of analytical grade.
Constructing AAV2-MORS196A-EGFP plasmid
DsAAV-MORS196A-EGFP plasmid was constructed by
replacing the GFP gene and the SV40 polyA site of the
dsAAV-CMV-EGFP gene with MORS196A-EGFP cDNA
at the BamHI and NotI sites, coupled to a miniature
polyA site. The recombinant viral stocks were produced
by the adenovirus-free, triple-plasmid cotransfection
method [4]. T he AA V vectors were purified by double
CsCl centrifugation and the titers were determined by
dot blot assay in the range of 1.0-3 × 1013 viral particles/
ml.
Experimental Animals
Twelve MOR-KO mice were kindly provided by Dr. Hor-
ace H. Loh [5]. The mice were housed in a room with a
12/12-h light/dark cycle, at a temperature of 25 ± 2°C and
a humidity of 55%. A standard rodent diet and water were
provided ad libitum. The care of animals was carried out
in accordance with institutional and international stan-
dards (Principles of Laboratory Animal Care, National
Institutes of Health), and the protocol had the approval of
the Institutional Animal Care and Use Committee of the
National Defense Medical Center (Taiwan, Republic of
China).
Direct microinjection of dsAAV vectors into the spinal cord 
dorsal horn
The mice were intraperitoneally (i.p.) injected with pen-
tobarbital (100 mg/kg), put under a dissecting micro-
scope, and then given a partial dorsal laminectomy. One
of the lumbar processes at L1-L2 was carefully removed
to expose a segment of spinal cord (S2-S3). Each mouse
was then placed in a spinal frame holder and mounted
under a stereotaxic frame with a microinjector attach-
ment that included a 10-μl Hamilton syringe with a
micro-tipped glass pipette. Four doses (0.5 μl) of the
dsAAV2-MORS196A-EGFP were bilaterally injected into
the spinal cord dorsal horn at a depth of approximately
0.3 mm. After surgery, the muscle and skin around the
wound were sutured and the wounds were held together
with three microsurgical wound clips.
Determining the antinociceptive effect of the drugs
Drug-induced antinociceptive effect was evaluated using
the tail-flick test. Using a tail-flick apparatus (Model
37360; Ugo Basile, Comerio VA, Italy), the intensity of the
heat source was set at 35, which allowed the basal tail-
flick latency to be controlled between 3 and 4.5 s for all
mice (cut-off time: 10 s). The area under the curve (AUC)
from the time-response curve or ED50 value was consid-
ered an index for the antinociceptive effect of the drugs.
Tail-flick latency was recorded at 30, 60, 90, 120, and 180
min after the drug had been injected. The AUC value was
obtained by calculating the area under the time-response
curve of the antinociceptive effect (test latency - basal
latency) from 0 to 180 min after the administration of the
drugs. The ED50 was determined using the up-and-down
method described by Dixon [6]. As shown in Fig. 1,
before microinjection of the vectors (pre, 0 day), the anti-
nociceptive effects of saline, morphine (M10; 10 mg/kg,
s.c.), and naloxone (Nx10; 10 mg/kg, s.c.) were tested as
the pretest data. From two to three weeks after the
d s A A V  i n j e c t i o n ,  t h e  m i c e  ( n  =  1 2 )  w e r e  t e s t e d  w i t h
either naloxone (10 mg/kg, s.c. on 14th day) or morphine
(10 mg/kg, s.c. on 21th day). The AUC values of tail-flick
t e s t  w e r e  c a l c u l a t e d  r e s p e c t i v e l y .  T o  t e s t  d r u g - i n d u c e d
tolerance, the mice were separated into 2 groups (n = 6)
and injected with either morphine (10 mg/kg, s.c.) or
naloxone (10 mg/kg, s.c.) twice a day (b.i.d.) for 4 days.
The ED50 of the drugs were evaluated before and after the
sub-chronic drugs treatment.Chen et al. Journal of Biomedical Science 2010, 17:28
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Fluorescence microscopy
The mice were anesthetized with pentobarbital (100 mg/
kg, i.p.) and transcardially perfused with Tyrone's cal-
cium-free buffer (116 mM NaCl, 5.36 mM KCl, 1.57 mM
MgCl2.6H2O, 0.405 mM MgSO4, 1.23 mM NaH2PO4, 5.55
mM Glucose, 26.2 mM NaHCO3, pH 7.4), and then with
4% paraformaldehyde in 0.1 M phosphate buffer. The
sacral spinal cord was dissected and placed in 20%
sucrose solution at 4°C overnight. The samples were then
embedded in OCT compound and immediately frozen at
-80°C. Serial transverse spinal cord slices (10 μgm) were
sectioned using a cryostat. The slices were mounted on
slides (Super Frost Plus; Menzel-Glaser, Braunschweig,
Germany) and a fluorescence microscope was used to
visualize the green fluorescence which represented the
dsAAV-mediated transgenic expression of MORS196A.
Statistical analysis
Data are means ± the standard error of the mean (SEM).
One-way analysis of variance (ANOVA) and the New-
man-Keuls test were used to analyze and compare the
data. Statistical significance was set at P < 0.05.
Results
DsAAV2-MORS196A-EGFP gene transfection and 
expression in vitro and in vivo
HEK-293 cells expressed the MORS196A-EGFP substan-
tially more 60 h (Fig. 2B) than 14 h (Fig. 2A) post-trans-
fection. The dsAAV-MORS196A-EGFP virus was then
harvested and purified. The viral titer used in this experi-
ment was 1 × 1013 vp/ml. To observe the expression of the
mutant receptor, the spinal cords of the mice were
removed and sectioned at 4th week. Significant green flu-
orescence that represented the expression of MORS196A
could be observed in the dorsal horn of sacral spinal cord
(Fig. 2D). In contrast, no significant green fluorescence
could be observed in the spinal cord of control mice (Fig.
2C).
Morphine was antinociceptive and induced tolerance after 
the transfection of the dsAAV2-MORS196A-EGFP gene
As expected, morphine (10 mg/kg, s.c.) did not have anti-
nociceptive effect in MOR-KO mice before transfection
of the dsAAV2-MORS196A-EGFP gene (Fig. 3A, 0 day
M10). However, 21 days after transfection, morphine (10
mg/kg. s.c.) showed significant antinociceptive effect
(Fig. 3A, 21 days M10). The AUC value of each mouse
was calculated and shown in Fig 4A. The mean AUC
value of the tail-flick test was 337.6 ± 51.7 (min × sec) 21
days post-transfection (Fig. 3B). The mice were then
treated with morphine (10 mg/kg, b.i.d., s.c.) for 4 days,
and the ED50 increased from 4.4 ± 1.0 to 7.2 ± 1.1 mg/kg,
which indicated the development of approximately 1.63
fold degree of tolerance (Table 1).
Naloxone elicited antinociceptive effects without tolerance 
in mice transfected with dsAAV2-MORS196A-EGFP gene
Naloxone (10 mg/kg, s.c.) also did not show antinocicep-
tive effect in MOR-KO mice before transfection of the
dsAAV2-MORS196A-EGFP gene. The mean AUC value
of 10 mg/kg of naloxone [94.3 ± 9.5 (min × sec)] was not
significantly different from that of saline [66.3 ± 7.9 (min
× sec)] before transfection (Fig. 5). However, significant
antinociceptive effects were presented from 30 min to
180 min after naloxone was administered subcutaneously
Figure 1 The experimental schedule of MOR-KO mice. Before mi-
croinjection of the dsAAV vectors (pre; 0 day), the antinociceptive ef-
fects of saline, morphine (M10; 10 mg/kg, s.c.), and naloxone (Nx10; 10 
mg/kg, s.c.) were tested by tail-flick test (TF) as the pretest data. After 
dsAAV injections, the mice (n = 12) were tested with either Nx10 (s.c., 
on 14th day) or M10 (s.c., on 21th day). The AUC values of tail-flick test 
were calculated respectively. Mice were then separated into 2 groups 
(n = 6) and injected with either M10 (s.c., b.i.d) or Nx10 (s.c., b.i.d.) for 4 
days. The ED50 of the drugs were evaluated before and after the sub-
chronic drugs treatment.
 
0    1       7       1 4      2 1      2 2       23  24      25     2 6    2 7   d a y s  
pre    Ц Ц            Nx10      M10    Ц                        Ц         
T F   d s A A V             TF(AUC)    TF(AUC)    TF(ED50)                     T F ( E D 50) 
M10 or Nx10 (bid.) 
Figure 2 Fluorescence micrographs in vitro and in vivo. (A)-(B) Rep-
resentative fluorescence micrographs of HEK-293 cells 14-60 h after 
they had been transfected with the dsAAV2-MORS196A-EGFP gene 
(magnification: 100×). (C) A representative spinal cord slice from a con-
trol mouse not transfected. (D) A representative spinal cord slice from 
MOR-KO mice four weeks after transfection (magnification: 100×). 
Scale bars = 40 μm.
( A ) 1 4   h                      ( C )   c o n t r o l  
(B)  6 0   h                      (D) 5 weeks MORS196AE Chen et al. Journal of Biomedical Science 2010, 17:28
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14 days after transfection (Fig. 5A, 14 days Nx10). The
AUC value of each mouse was calculated and shown in
Fig 4B. The mean AUC value of the same dose of nalox-
one significantly increased to 304.7 ± 47.4 (min × sec) 14
days after transfection (Fig. 5B). The ED50 of naloxone
(8.4 ± 1.2 mg/kg) did not change after 4 days of sub-
chronic treatment with naloxone (10 mg/kg, b.i.d., s.c.),
which indicated that there was no tolerance developed to
naloxone (Table 1).
Discussion
In this study, double-strand AA V2 was chosen for neu-
ronal expression of the mutant MORS196A receptor. Its
extensive transduction into neurons and long-term gene
expression with no apparent toxicity made this recom-
bined virus as a potential candidate vector for gene ther-
apy [7]. The double-strand AAV2 vector had been
demonstrated the efficiency of transferring the target
gene to the central nervous system [8-10]. After single
injection of MORS196A gene, the local and sustained
MORS196A receptor expression in dorsal horn of sacral
to lumbar spinal cord were found in these MOR knock-
out mice. Our findings further confirm the gene transfer
efficiency of recombined AA V2 in central nervous sys-
tem.
In the present study we only got totally 12 male MOR
knock-out mice. Therefore we have tried to examine the
effect of morphine at a dose of 5 mg/kg (s.c.) on 7th day
initially and found morphine had already shown signifi-
cant antinociceptive effect (data not shown). Later on
14th day and 21th day, the effects of naloxone (s.c.) or mor-
phine at a dose of 10 mg/kg (s.c.) were determined sepa-
rately in all 12 mice. In order not to confuse the reader,
we have deleted the data of morphine at a dose of 5 mg/kg
(s.c.) on 7th day and compared the pretest data of mor-
phine (10 mg/kg, s.c.) with the same dose of morphine on
21th  day post-transfection (21 days M10) (Fig 3). We
found that morphine at a dose of 10 mg/kg did not have
significant antinociceptive effect in MOR-KO mice
before they were transfected with the MORS196A-EGFP
gene. Previous studies also reported that morphine at
doses up to 56 mg/kg did not show significant antinocice-
ptive effect in homozygous MOR-KO mice [11,12,5].
However, after 21 days transfection of MORS196A-EGFP
gene, 10 mg/kg (s.c.) morphine showed significant anti-
Table 1: Tolerance induced by morphine but not naloxone in MOR-KO mice that had been transfected with the dsAAV2-
MORS196A-EGFP gene
ED50 of morphine
(mg/kg)
ED50 of naloxone
(mg/kg)
Acute effect 4.4 ± 1.0 8.4 ± 1.2
Sub-chronic effect 7.2 ± 1.1 (×1.63) 8.4 ± 1.2
The ED50 values of morphine and naloxone that inhibit the tail-flick responses were determined using the up-and-down method 3 weeks after 
gene transfer. The mice were then sub-chronically treated with morphine (10 mg/kg) or naloxone (10 mg/kg) subcutaneously twice a day for 
4 days. ED50 values were then redetermined. Data are means ± the standard error of the mean (SEM) (n = 6).
Figure 3 Antinociceptive effect of morphine in MOR-KO mice de-
termined using tail-flick tests before and after they had been 
transfected with the dsAAV2-MORS196A-EGFP gene. (A) The time-
response curves for saline and 10 mg/kg of morphine before (0 day 
M10) and 21 days (21 days M10) after transfection. ***P < 0.001 (vs. sa-
line). (B) The mean AUC (area under curve) values for each treatment in 
Fig. 3A (n = 12). ***P < 0.001 (vs. saline).Chen et al. Journal of Biomedical Science 2010, 17:28
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nociceptive effect. We also found that 1.63 fold of toler-
ance developed after the transfected MOR-KO mice had
been sub-chronically treated with morphine (10 mg/kg,
s.c., b.i.d.) for 4 days. These results resembled the previ-
ous MORS196A knock-in mice study, morphine could
elicit the antinociceptive effect and induced tolerance [2].
Our findings indicate that morphine can activate the
exogenously delivered and expressed mutant MOR
receptor in spinal cord and induces tolerance in MOR-
KO mice. On the other hand, naloxone, an opioid recep-
tor antagonist, was also shown significant antinociceptive
effect but did not cause tolerance in this local
MORS196A gene transfer MOR-KO mice. Previous
reports have indicated that the delta opioid receptor
(DOR) plays an essential role in the formation of opioid
tolerance [13]. Co-administration of morphine with delta
opioid receptor (DOR) antagonists, thus inactivating the
DORs, blocks morphine tolerance in mice [13]. The loss
of morphine tolerance in DOR-KO mice also had been
documented [14]. Therefore, it is reasonable to surmise
that an opioid antagonist (naloxone) that activates an
exogenously delivered mutant MOR receptor and inacti-
vates the endogenous DOR will inhibit the development
of tolerance to that opioid. The present data further sup-
port our previous findings in ICR mice [3] and suggest
that, if the mutant opioid receptor can be delivered to the
pain related pathway, opioid antagonist mediated activa-
tion of this mutant receptor should result in pain relieve
without the development of tolerance.
We also found that not all of the transfected MOR-KO
mice responded to morphine and naloxone treatment.
Although every mouse showed the EGFP expression in
the sacral and lumbar spinal cord, only 9 of 12 (75%) mice
responded significantly to the naloxone or morphine
treatment (AUC > 200 min × sec, Fig 4). Except the indi-
vidual variation, the possible reason for this may be that
Figure 4 Antinociceptive effects of morphine and naloxone in in-
dividual MOR-KO mice before and after they had been transfect-
ed with the dsAAV2-MORS196A-EGFP gene. (A) The AUC (area 
under curve) values of morphine 10 mg/kg (s.c.) before (0 day M10) 
and 21 days (21 days M10) after transfection. (B) The AUC values of 10 
mg/kg of naloxone (Nx10, s.c.) before (0 day Nx10) and 14 days (14 days 
Nx10) after transfection.
Figure 5 Antinociceptive effect of naloxone in MOR-KO mice de-
termined using tail-flick tests before and after they had been 
transfected with the dsAAV2-MORS196A-EGFP gene. (A) The time-
response curves for saline and 10 mg/kg naloxone before (0 day Nx10) 
and 14 days (14 days Nx10) after transfection. *P < 0.05, **P < 0.01, ***P 
< 0.001 (vs. saline). (B) The mean AUC (area under curve) values for 
each treatment in Fig. 5A (n = 12). ***P < 0.001 (vs. saline).Chen et al. Journal of Biomedical Science 2010, 17:28
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MORS196A-EGFP could express not only at the primary
sensory neuron, but also at many other neurons that
might not be related to the antinociception. For achieve-
ment of the ideal antinociception, the neuron specific
promoter or vector must be developed for the more effi-
cient gene transfer in future study.
Our results provided a possibility of dsAAV2 mediated
local gene transfer and use of opioid antagonists to treat
chronic pain without tolerance in future clinic study.
However , in the present study , we have used the direct
local injection of vector into the local site of spinal cord.
Although spinal-cord microinjection was convenient for
the present study, it is not ideal for human therapy.
Intrathecal transfection into the subarachnoid space of
the spine will be less invasive and more patient-friendly.
Moreover, morphine-dependent patients may undergo
withdrawal symptoms when they begin naloxone treat-
ment. Therefore, a carefully designed treatment must be
developed. A local intrathecal delivery of the mutant
MOR and gradual weaning from morphine and then
using naloxone may be ideal strategies for pain therapy in
morphine-dependent patients. To achieve this goal, more
studies on the safety and the efficiency of dsAAV medi-
ated local gene transfer still need carefully design and
monitor in future study.
Conclusion
DsAAV2 efficiently delivered the target gene
(MORS196A) to the spinal cord in MOR-KO mice. In
vivo  transfecting the MORS196A gene into the pain
related nervous pathway and systemically administering
naloxone activated the local expressed mutant MOR and
induced antinociceptive effect without tolerance. This
treatment may become an alternative to traditional opi-
oid agonists for pain management.
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